Monosialoganglioside GM2 in GLS can downregulate the phosphorylation of EGFR at position 1045, inhibit the phosphorylation of growth factors and the activation of growth factors, and then, inhibit the motility and migration of tumor cells [64–66]; GM2 (also known as GA2) expression level is lower in cancer tissues, and the ability to inhibit cell growth is poor. Here, EGFR is linked to neoplasm.